Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rational discovery of a highly novel and selective mTOR inhibitor.
Jin S, Mikami S, Scorah N, Chen Y, Halkowycz P, Shi L, Kahana J, Vincent P, de Jong R, Atienza J, Fabrey R, Zhang L, Lardy M. Jin S, et al. Among authors: zhang l. Bioorg Med Chem Lett. 2019 Nov 1;29(21):126659. doi: 10.1016/j.bmcl.2019.126659. Epub 2019 Sep 3. Bioorg Med Chem Lett. 2019. PMID: 31543303
Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P, Shi L, Matuszkiewicz J, Balakrishna D, Hoshino T, Zhang L, Elliott S, Fabrey R, Lee B, Halkowycz P, Sang B, Ishino S, Nomura T, Teratani M, Ohta Y, Grimshaw C, Paraselli B, Satou T, de Jong R. Farrell P, et al. Among authors: zhang l. Mol Cancer Ther. 2013 Apr;12(4):460-70. doi: 10.1158/1535-7163.MCT-12-0657. Epub 2013 Jan 28. Mol Cancer Ther. 2013. PMID: 23358665
Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Nie Z, Feher V, Natala S, McBride C, Kiryanov A, Jones B, Lam B, Liu Y, Kaldor S, Stafford J, Hikami K, Uchiyama N, Kawamoto T, Hikichi Y, Matsumoto S, Amano N, Zhang L, Hosfield D, Skene R, Zou H, Cao X, Ichikawa T. Nie Z, et al. Among authors: zhang l. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3662-6. doi: 10.1016/j.bmcl.2013.02.083. Epub 2013 Feb 27. Bioorg Med Chem Lett. 2013. PMID: 23664874 Clinical Trial.
Structure-based design and SAR development of 5,6-dihydroimidazolo[1,5-f]pteridine derivatives as novel Polo-like kinase-1 inhibitors.
Kiryanov A, Natala S, Jones B, McBride C, Feher V, Lam B, Liu Y, Honda K, Uchiyama N, Kawamoto T, Hikichi Y, Zhang L, Hosfield D, Skene R, Zou H, Stafford J, Cao X, Ichikawa T. Kiryanov A, et al. Among authors: zhang l. Bioorg Med Chem Lett. 2017 Mar 1;27(5):1311-1315. doi: 10.1016/j.bmcl.2016.10.009. Epub 2016 Oct 15. Bioorg Med Chem Lett. 2017. PMID: 28169164
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.
Murphy ST, Atienza J, Brown JW, Cheruvallath ZS, Cukierski MJ, Fabrey R, Keung W, Kwok L, O'Connell S, Tang M, Vanderpool DL, Vincent PW, Zhang L, Marx MA. Murphy ST, et al. Among authors: zhang l. ACS Med Chem Lett. 2023 Oct 25;14(11):1544-1550. doi: 10.1021/acsmedchemlett.3c00351. eCollection 2023 Nov 9. ACS Med Chem Lett. 2023. PMID: 37970587 Free PMC article.
TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y, Honda K, Hikami K, Miyashita H, Kaieda I, Murai S, Uchiyama N, Hasegawa M, Kawamoto T, Sato T, Ichikawa T, Cao S, Nie Z, Zhang L, Yang J, Kuida K, Kupperman E. Hikichi Y, et al. Among authors: zhang l. Mol Cancer Ther. 2012 Mar;11(3):700-9. doi: 10.1158/1535-7163.MCT-11-0762. Epub 2011 Dec 21. Mol Cancer Ther. 2012. PMID: 22188812
124,428 results
You have reached the last available page of results. Please see the User Guide for more information.